Veru announces appointment of jason davies to lead emea, latam and apac infectious disease franchise for veru international focused on hospitalized covid-19 patients

Miami, aug. 19, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral and ards-related diseases and for the management of breast and prostate cancers, today announced the appointment of jason davies as executive vice president – general manager of europe, the middle east and africa (emea), latin america (latam), and asia pacific (apac) for veru's infectious disease franchise for veru international.
VERU Ratings Summary
VERU Quant Ranking